Analyst Price Targets — BNTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:37 am | — | Morgan Stanley | $119.00 | $94.29 | TheFly | BioNTech price target lowered to $119 from $126 at Morgan Stanley |
| May 27, 2026 8:43 am | — | UBS | $135.00 | $92.25 | TheFly | BioNTech upgraded to Buy from Neutral at UBS |
| May 21, 2026 8:24 pm | — | Bernstein | $96.00 | $90.93 | TheFly | BioNTech initiated with a Market Perform at Bernstein |
| May 6, 2026 11:32 am | — | Canaccord Genuity | $158.00 | $95.50 | TheFly | BioNTech price target lowered to $158 from $171 at Canaccord |
| April 10, 2026 12:55 pm | Terence Flynn | Morgan Stanley | $126.00 | $93.38 | TheFly | BioNTech price target raised to $126 from $125 at Morgan Stanley |
| March 11, 2026 1:15 pm | Evan David Seigerman | BMO Capital | $128.00 | $90.52 | StreetInsider | BioNTech (BNTX) PT Lowered to $128 at BMO Capital |
| March 10, 2026 7:41 pm | Akash Tewari | Jefferies | $138.00 | $83.89 | StreetInsider | BioNTech (BNTX) PT Lowered to $138 at Jefferies |
| March 10, 2026 6:28 pm | Asthika Goonewardene | Truist Financial | $155.00 | $83.89 | StreetInsider | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes |
| March 10, 2026 4:29 pm | — | Morgan Stanley | $128.00 | $83.89 | StreetInsider | BioNTech (BNTX) PT Lowered to $128 at BofA Securities |
| February 2, 2026 11:03 am | — | Leerink Partners | $113.00 | $113.75 | TheFly | BioNTech downgraded to Market Perform from Outperform at Leerink |
Latest News for BNTX
On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.
They may not remain cheap for too much longer.
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper reported on Friday.
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.